Market Place
Sourcing Support
Maze Therapeutics Reports Data for MZE829 in APOL1 Kidney Disease
25 Oct 2024 //
BUSINESSWIRE
Maze Therapeutics To Present Data On MZE829 And MZE782
15 Oct 2024 //
BUSINESSWIRE
Maze Therapeutics Starts Phase 1 Trial Of MZE782 For Kidney Disease
01 Oct 2024 //
BUSINESSWIRE
Maze lands new partner for Pompe drug, after Sanofi pact came apart
11 May 2024 //
BIOPHARMADIVE
Shionogi, Maze Pompe Disease Candidate MZE001 Deal
10 May 2024 //
BUSINESSWIRE
Maze Therapeutics to Participate in Upcoming Investor Conferences
26 Feb 2024 //
BUSINESSWIRE
Maze to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Maze Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829
14 Dec 2023 //
BUSINESSWIRE
Statement on FTC challenge to proposed license agreement with Maze Therapeutics
12 Dec 2023 //
BUSINESSWIRE
Maze Therapeutics Highlights Preclinical Data Supporting Advancement of APOL1
04 Nov 2023 //
BUSINESSWIRE
Maze Therapeutics to Present New Data for APOL1 Kidney Disease
13 Oct 2023 //
BUSINESSWIRE
Maze to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
21 Sep 2023 //
BUSINESSWIRE
Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
01 Jun 2023 //
BUSINESSWIRE
Sanofi bets $750M to enter glycogen-lined Maze deal with lead asset
02 May 2023 //
FIERCE BIOTECH
Maze Announces Data Supporting MZE001 as a Potential Treatment for Pompe Disease
22 Mar 2023 //
BUSINESSWIRE
Maze Therapeutics Announces Positive PI Results from Trial Evaluating MZE001
27 Feb 2023 //
BUSINESSWIRE
Maze Therapeutics to Present Phase 1 Results from Trial Evaluating MZE001
16 Feb 2023 //
BUSINESSWIRE
Maze reveals positive first look at PhI Pompe disease candidate
15 Dec 2022 //
ENDPTS
Maze Therapeutics Announces Completion of Phase 1 Trial Evaluating MZE001
15 Dec 2022 //
BUSINESSWIRE
Maze Presents Data Highlighting Potential of APOL1 Inhibitor Program
04 Nov 2022 //
BUSINESSWIRE
Maze Therapeutics Appoints Harold Bernstein as President, R&D & CMO
13 Oct 2022 //
BUSINESSWIRE
Maze Therapeutics Appoints Harold Bernstein as President, R&D and CMO
13 Oct 2022 //
BUSINESSWIRE
Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors
22 Sep 2022 //
BUSINESSWIRE
FDA grants Orphan Drug status to Maze’s Pompe disease treatment
01 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Maze Announces FDA Orphan Drug Designation Granted to MZE001
31 Aug 2022 //
BUSINESSWIRE
Maze Tx to Publish Novel Mechanism Linking Genetic Drivers of ALS and FTD
23 Feb 2022 //
BUSINESSWIRE
Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001
17 Feb 2022 //
BUSINESSWIRE
Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001
10 Feb 2022 //
BUSINESSWIRE
Maze to Present Preclinical Data Highlighting MZE001 for Pompe Disease
31 Jan 2022 //
BUSINESSWIRE
